MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Soleno Therapeutics Net Income 2011-2025 | SLNO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Soleno Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -176 M | -39 M | -24.1 M | -30.9 M | -24.6 M | -30.8 M | -13.3 M | -15.7 M | -12.1 M | -15.9 M | -13.9 M | -3.71 M | -6.48 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.71 M | -176 M | -31.3 M |
Quarterly Net Income Soleno Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 M | -4.71 M | -43.8 M | - | -76.6 M | -21.9 M | -21.4 M | - | -10.9 M | -8.48 M | -8.36 M | - | -6.13 M | -6.72 M | -5.72 M | - | -8.14 M | -11 M | -8.95 M | - | -8.54 M | -7.38 M | -5.86 M | - | 889 K | -10 M | -7.03 M | - | -2.74 M | -7.06 M | -3.8 M | - | -3.79 M | -3.97 M | -2.89 M | - | -2.75 M | -3.51 M | -3.19 M | - | -3.29 M | 1.88 M | -11.7 M | - | -13.2 M | -13.2 M | -13.2 M | - | -1.59 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26 M | -76.6 M | -9.26 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M |  USA |
|
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 38.85 | 2.32 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.36 | -4.05 % | $ 176 M |  China |
 |
Brainsway Ltd.
BWAY
|
-6.46 M | $ 17.05 | -2.15 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
3.9 B | $ 227.08 | -2.28 % | $ 166 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-865 M | $ 101.58 | 0.21 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 27.13 | 0.26 % | $ 820 M | USA |
 |
BioNano Genomics
BNGO
|
-112 M | $ 1.63 | -2.11 % | $ 2.07 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
542 M | $ 66.91 | -2.94 % | $ 25.8 B | USA |
 |
DarioHealth Corp.
DRIO
|
-59.4 M | $ 11.92 | -6.58 % | $ 338 M | Israel |
 |
Illumina
ILMN
|
-1.22 B | $ 134.29 | -1.58 % | $ 21.4 B | USA |
 |
IQVIA Holdings
IQV
|
1.37 B | $ 221.54 | -1.96 % | $ 40.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Lantheus Holdings
LNTH
|
312 M | $ 66.11 | 4.76 % | $ 4.57 B | USA |
 |
Guardant Health
GH
|
-436 M | $ 102.09 | 0.7 % | $ 12.5 B | USA |
 |
CareDx, Inc
CDNA
|
-190 M | $ 20.44 | 3.23 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
-112 M | $ 105.26 | 4.46 % | $ 4.15 B | USA |
 |
Anixa Biosciences
ANIX
|
-12.6 M | $ 3.59 | -25.21 % | $ 115 K | USA |
 |
Co-Diagnostics
CODX
|
-35.3 M | $ 0.34 | -2.96 % | $ 9.98 M | USA |
 |
Myriad Genetics
MYGN
|
-127 M | $ 7.26 | -0.62 % | $ 658 M | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 6.86 | -2.63 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
31 M | $ 17.81 | 2.24 % | $ 437 M | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
746 M | $ 263.51 | -0.46 % | $ 22.1 B | USA |
 |
Organovo Holdings
ONVO
|
-2.49 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
12 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
-307 M | $ 2.13 | -1.61 % | $ 540 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 26.6 | -1.52 % | $ 20 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
-4.15 M | - | -1.84 % | $ 15.3 M | USA |
 |
Charles River Laboratories International
CRL
|
22.2 M | $ 192.57 | -0.96 % | $ 9.89 B | USA |
 |
Quidel Corporation
QDEL
|
810 M | $ 28.79 | -2.93 % | $ 1.21 B | USA |
 |
Quotient Limited
QTNT
|
-111 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
RadNet
RDNT
|
2.79 M | $ 75.0 | -4.65 % | $ 5.48 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
871 M | $ 182.21 | 0.35 % | $ 20.2 B | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 7.94 | -1.0 % | $ 1.03 B | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 186.28 | -1.92 % | $ 15.4 B |  Irlanda |